GlycoMimetics Company Insiders
GLYC Stock | USD 0.28 0.01 3.70% |
About 84 percent of GlycoMimetics' insiders are selling. The analysis of the overall insider sentiment regarding GlycoMimetics suggests that quite a large number of insiders are terrified. GlycoMimetics employs about 4 people. The company is managed by 11 executives with a total tenure of roughly 47 years, averaging almost 4.0 years of service per executive, having 0.36 employees per reported executive.
Rachel King CEO President CEO, Founder, Director |
Armand Girard President Senior Vice President Strategy and Corporate Development |
Insider Sentiment 16
Mostly Selling
Selling | Buying |
Latest Trades
2024-08-07 | Public Equities L.P. Invus | Disposed 61488 @ 0.18 | View | ||
2024-08-05 | Public Equities L.P. Invus | Disposed 164523 @ 0.19 | View | ||
2024-08-01 | Public Equities L.P. Invus | Disposed 63564 @ 0.22 | View | ||
2024-07-29 | Public Equities L.P. Invus | Disposed 363949 @ 0.24 | View | ||
2024-07-26 | Public Equities L.P. Invus | Disposed 258335 @ 0.24 | View | ||
2024-06-20 | Edwin Rock | Acquired 190000 @ 0.25 | View |
Monitoring GlycoMimetics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
GlycoMimetics |
GlycoMimetics Management Team Effectiveness
The company has return on total asset (ROA) of (0.7204) % which means that it has lost $0.7204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7325) %, meaning that it created substantial loss on money invested by shareholders. GlycoMimetics' management efficiency ratios could be used to measure how well GlycoMimetics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 19, 2025, Return On Tangible Assets is expected to decline to -0.98. The current year's Return On Capital Employed is expected to grow to -7.16. At present, GlycoMimetics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 11.6 B, whereas Non Current Assets Total are forecasted to decline to 0.00.As of March 19, 2025, Common Stock Shares Outstanding is expected to decline to about 35.6 M. In addition to that, Net Loss is expected to decline to about (44.1 M)
GlycoMimetics Workforce Comparison
GlycoMimetics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,059. GlycoMimetics adds roughly 4.0 in number of employees claiming only tiny portion of equities under Health Care industry.
GlycoMimetics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GlycoMimetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on GlycoMimetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, GlycoMimetics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
GlycoMimetics Notable Stakeholders
A GlycoMimetics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as GlycoMimetics often face trade-offs trying to please all of them. GlycoMimetics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting GlycoMimetics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Rachel King | President CEO, Founder, Director | Profile | |
Harout Semerjian | President CEO | Profile | |
Armand Girard | Senior Vice President Strategy and Corporate Development | Profile | |
Brian Hahn | CFO and Principal Accounting Officer | Profile | |
John Magnani | Chief Scientific Officer, VP and Director | Profile | |
Edwin MD | Senior Officer | Profile | |
Chinmaya Rath | Senior Officer | Profile | |
Stephanie CPA | Vice Accounting | Profile | |
Bruce Johnson | Senior Officer | Profile | |
Shantha Tyavanagimatt | Senior Operations | Profile | |
Christian DinneenLong | General Secretary | Profile |
About GlycoMimetics Management Performance
The success or failure of an entity such as GlycoMimetics often depends on how effective the management is. GlycoMimetics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of GlycoMimetics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the GlycoMimetics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.94) | (0.98) | |
Return On Capital Employed | (7.54) | (7.16) | |
Return On Assets | (0.94) | (0.98) | |
Return On Equity | (1.10) | (1.16) |
Please note, the presentation of GlycoMimetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, GlycoMimetics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of GlycoMimetics' management manipulating its earnings.
GlycoMimetics Workforce Analysis
Traditionally, organizations such as GlycoMimetics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare GlycoMimetics within its industry.GlycoMimetics Manpower Efficiency
Return on GlycoMimetics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 9.5B | |
Net Loss Per Executive | 3.4B | |
Working Capital Per Employee | 1.3M | |
Working Capital Per Executive | 483.1K |
Complementary Tools for GlycoMimetics Stock analysis
When running GlycoMimetics' price analysis, check to measure GlycoMimetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlycoMimetics is operating at the current time. Most of GlycoMimetics' value examination focuses on studying past and present price action to predict the probability of GlycoMimetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlycoMimetics' price. Additionally, you may evaluate how the addition of GlycoMimetics to your portfolios can decrease your overall portfolio volatility.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Transaction History View history of all your transactions and understand their impact on performance | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |